BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...

After assessing tissue samples from 46 patients, Monte Rosa said expression was lower than expected in some tumor types. None of the sampled non-small cell lung cancer patients had high L- or N-MYC.

BOSTON - Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical-stage biotechnology company with a market capitalization of $580 million and an impressive 120% surge in share price over the past ...

This combination therapy also showed potential in delaying resistance to CDK4/6 inhibitors, a common issue faced in breast cancer treatment. Sharon Townson, Ph.D., Chief Scientific Officer at Monte ...

CDK2-directed MGD drove deep tumor regression in preclinical models of HR-positive/HER2-negative breast cancer when combined with either a CDK4/6 inhibitor or a CDK4 ...

CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and ...

BOSTON - Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical-stage biotechnology company with a market capitalization of $580 million and an impressive 120% surge in share price over the past six ...